TPCW
RXRX icon

TD Private Client Wealth’s Recursion Pharmaceuticals RXRX Stock Holding History

TD Private Client Wealth’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-350
Closed -$1.71K – 1710
2025
Q3 		$1.71K Buy
350
+224
+178% +$1.18K ﹤0.01% 1264
2025
Q2 		$638 Buy
+126
New +$619 ﹤0.01% 1334

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

TD Private Client Wealth's RXRX Position: Q4 2025 in Review

TD Private Client Wealth sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 350 shares — an estimated $1.71K sold.

TD Private Client Wealth first reported a position in RXRX in Q2 2025 and held it in 2 quarters. The position peaked at $1.71K in Q3 2025. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

  • TD Private Client Wealth reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • TD Private Client Wealth sold 350 Recursion Pharmaceuticals shares in Q4 2025, an estimated $1.71K.
  • TD Private Client Wealth first reported a position in Recursion Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • TD Private Client Wealth's Recursion Pharmaceuticals position peaked at $1.71K in Q3 2025.
  • 333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on TD Private Client Wealth's 13F filing for Q4 2025, filed 5 Feb 2026.